Company Announcement no. 14/2013
Hørsholm, Denmark, May 30, 2013
Today, the Board of Directors of Veloxis Pharmaceuticals A/S (the "Company") has decided to annul 18,728,293 warrants, which the Company has repurchased from a number of employees.
The amendment of the Articles of Association pursuant to the annulment of warrants has today been registered with the Danish Business Authority. The new Articles of Association of Veloxis Pharmaceuticals A/S are attached.
For more information, please contact:
Veloxis Pharmaceuticals A/S
Bill Polvino Johnny Stilou
President & CEO EVP, Chief Financial Officer
Mobile: +1 917 647 9107 Mobile: +45 21 227 227
Email: wjp@veloxis.com Email: jst@veloxis.com
About Veloxis Pharmaceuticals
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is LCP-Tacro for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.